儿童免疫介导坏死性肌病的治疗进展
Progress in the Treatment of Immune-Mediated Necrotizing Myopathy in Children
DOI: 10.12677/acm.2026.1641484, PDF,   
作者: 张 欣, 洪思琦*：重庆医科大学附属儿童医院神经内科，国家儿童健康与疾病临床医学研究中心，儿童发育疾病研究教育部重点实验室，儿童神经发育与认知障碍重庆市重点实验室，重庆
关键词: 儿童；免疫介导坏死性肌病；生物制剂；靶向治疗；Children； Immune-Mediated Necrotizing Myopathy； Biological Agents； Targeted Therapy
摘要: 儿童免疫介导坏死性肌病IMNM (Immune-Mediated Necrotizing Myopathy)是儿童特发性炎性肌病中的重要亚型，具有起病缓、易误诊及潜在预后不良的特点，目前该病的治疗尚缺乏基于儿科高质量证据的文献。传统免疫疗法如糖皮质激素、甲氨蝶呤、环磷酰胺等仍是一线治疗，但部分患者存在疗效不佳或无法耐受的问题。靶向治疗及新型细胞治疗的发展为难治性病例带来新希望。本文系统综述儿童IMNM及其治疗策略特别是新型治疗策略，并展望未来个体化精准治疗的研究方向。
Abstract: Immune Mediated Necrotizing Myopathy (IMNM) in children is an important subtype of idiopathic inflammatory myopathy, characterized by slow onset, easy misdiagnosis, and potential poor prognosis. Currently, there is a lack of high-quality pediatric evidence for the treatment of this disease. Traditional immunotherapy such as glucocorticoids, methotrexate, cyclophosphamide, etc. are still first-line treatments, but some patients have poor efficacy or intolerance issues. The development of targeted therapy and novel cell therapies brings new hope to difficult-to-treat cases. This article provides a systematic review of IMNM in children and its treatment strategies, especially new treatment strategies, and looks forward to future research directions for personalized precision therapy.
文章引用：张欣, 洪思琦. 儿童免疫介导坏死性肌病的治疗进展[J]. 临床医学进展, 2026, 16(4): 2352-2358. https://doi.org/10.12677/acm.2026.1641484

参考文献

[1] Karakas, C., Sah, J., Seidman, R., Chari, G., Hisamoto, Y., Cracco, J., et al. (2018) A Child with Antibody‐Negative Immune‐Mediated Necrotizing Myopathy. Muscle & Nerve, 59, E10-E13. [Google Scholar] [CrossRef] [PubMed]
[2] Hoogendijk, J.E., Amato, A.A., Lecky, B.R., Choy, E.H., Lundberg, I.E., Rose, M.R., et al. (2004) 119th ENMC International Workshop: Trial Design in Adult Idiopathic Inflammatory Myopathies, with the Exception of Inclusion Body Myositis, 10-12 October 2003, Naarden, the Netherlands. Neuromuscular Disorders, 14, 337-345. [Google Scholar] [CrossRef] [PubMed]
[3] Mohassel, P., Landon-Cardinal, O., Foley, A.R., Donkervoort, S., Pak, K.S., Wahl, C., et al. (2019) Anti-Hmgcr Myopathy May Resemble Limb-Girdle Muscular Dystrophy. Neurology Neuroimmunology & Neuroinflammation, 6, e523. [Google Scholar] [CrossRef] [PubMed]
[4] Binns, E.L., Moraitis, E., Maillard, S., Tansley, S., McHugh, N., Jacques, T.S., et al. (2017) Effective Induction Therapy for Anti-SRP Associated Myositis in Childhood: A Small Case Series and Review of the Literature. Pediatric Rheumatology, 15, Article No. 77. [Google Scholar] [CrossRef] [PubMed]
[5] Yang, M., Bi, Z., Li, Z., Zhan, J., Gao, H., Zhang, Q., et al. (2025) The Pathogenesis of Immune-Mediated Necrotizing Myopathy: Progress and Therapeutic Implications. Biomedicine & Pharmacotherapy, 191, Article ID: 118525. [Google Scholar] [CrossRef] 
[6] Allenbach, Y., Mammen, A.L., Benveniste, O., Stenzel, W. and Immune-Mediated Necrotizing Myopathies Working Group (2018) 224th ENMC International Workshop: Clinico-Sero-Pathological Classification of Immune-Mediated Necrotizing Myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscular Disorders, 28, 87-99.
[7] Ma, X. and Bu, B. (2022) Anti-SRP Immune-Mediated Necrotizing Myopathy: A Critical Review of Current Concepts. Frontiers in Immunology, 13, Article 1019972. [Google Scholar] [CrossRef] [PubMed]
[8] Allenbach, Y., Benveniste, O., Stenzel, W. and Boyer, O. (2020) Immune-Mediated Necrotizing Myopathy: Clinical Features and Pathogenesis. Nature Reviews Rheumatology, 16, 689-701. [Google Scholar] [CrossRef] [PubMed]
[9] Ma, X. and Bu, B. (2022) Anti-SRP Immune-Mediated Necrotizing Myopathy: A Critical Review of Current Concepts. Frontiers in Immunology, 13, Article ID: 1019972. [Google Scholar] [CrossRef] [PubMed]
[10] Li, C., Liu, H., Yang, L., Liu, R., Yin, G. and Xie, Q. (2024) Immune-Mediated Necrotizing Myopathy: A Comprehensive Review of the Pathogenesis, Clinical Features, and Treatments. Journal of Autoimmunity, 148, Article ID: 103286. [Google Scholar] [CrossRef] [PubMed]
[11] Kishi, T., Rider, L.G., Pak, K., Barillas‐Arias, L., Henrickson, M., McCarthy, P.L., et al. (2017) Association of Anti-3‐Hydroxy‐3‐Methylglutaryl‐Coenzyme a Reductase Autoantibodies with DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients. Arthritis Care & Research, 69, 1088-1094. [Google Scholar] [CrossRef] [PubMed]
[12] Mohassel, P., Foley, A.R., Donkervoort, S., Fequiere, P.R., Pak, K., Bönnemann, C.G., et al. (2017) Anti-3‐hydroxy‐3‐methylglutaryl‐coenzyme a Reductase Necrotizing Myopathy Masquerading as a Muscular Dystrophy in a Child. Muscle & Nerve, 56, 1177-1181. [Google Scholar] [CrossRef] [PubMed]
[13] Morikawa, S., Murakami, T., Yamazaki, H., Izumi, A., Saito, Y., Hamakubo, T., et al. (2005) Analysis of the Global RNA Expression Profiles of Skeletal Muscle Cells Treated with Statins. Journal of Atherosclerosis and Thrombosis, 12, 121-131. [Google Scholar] [CrossRef] [PubMed]
[14] Suh, J. and Amato, A.A. (2024) Management of Immune‐Mediated Necrotizing Myopathy. Muscle & Nerve, 70, 166-172. [Google Scholar] [CrossRef] [PubMed]
[15] Weeding, E. and Tiniakou, E. (2021) Therapeutic Management of Immune-Mediated Necrotizing Myositis. Current Treatment Options in Rheumatology, 7, 150-160. [Google Scholar] [CrossRef] [PubMed]
[16] Oldroyd, A.G.S., Lilleker, J.B., Amin, T., Aragon, O., Bechman, K., Cuthbert, V., et al. (2022) British Society for Rheumatology Guideline on Management of Paediatric, Adolescent and Adult Patients with Idiopathic Inflammatory Myopathy. Rheumatology, 61, 1760-1768. [Google Scholar] [CrossRef] [PubMed]
[17] Deakin, C.T., Campanilho‐Marques, R., Simou, S., Moraitis, E., Wedderburn, L.R., Pullenayegum, E., et al. (2018) Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling. Arthritis & Rheumatology, 70, 785-793. [Google Scholar] [CrossRef] [PubMed]
[18] Olivo Pallo, P.A., de Souza, F.H.C., Miossi, R. and Shinjo, S.K. (2018) Mycophenolate Mofetil in Patients with Refractory Systemic Autoimmune Myopathies: Case Series. Advances in Rheumatology, 58, Article No. 34. [Google Scholar] [CrossRef] [PubMed]
[19] Amarante, I., Faustino, C., Mota, B., Cascais, M., Almeida, J. and Valentim, M. (2025) Full Recovery over One Year of the Overlap Syndrome Scleromyositis to Maintenance Therapy with Mycophenolate Mofetil and Rituximab, Which Relapsed within 8 Months of Discontinuation. European Journal of Case Reports in Internal Medicine, 12, Article 005154. [Google Scholar] [CrossRef] [PubMed]
[20] Galindo, M., Cabello, A., Joven, B., Alonso, A., Carreira, P., Porta, J., Ricoy, J.R., Mateo, I. and Pablos, J.L. (2005) Mycophenolate Mofetil Induced Myopathy in a Patient with Lupus Nephritis. The Journal of Rheumatology, 32, 188-190.
[21] Feng, F., Li, Y., Ji, S., Wang, Q. and Bu, B. (2019) Tacrolimus Combined with Corticosteroids Effectively Improved the Outcome of a Cohort of Patients with Immune-Mediated Necrotising Myopathy. Clinical and Experimental Rheumatology, 37, 740-747.
[22] Dalakas, M.C. (2004) Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. JAMA, 291, 2367-2375. [Google Scholar] [CrossRef] [PubMed]
[23] Worch, J., Makarova, O. and Burkhardt, B. (2015) Immunreconstitution and Infectious Complications after Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults? Cancers, 7, 305-328. [Google Scholar] [CrossRef] [PubMed]
[24] Suh, J. and Amato, A.A. (2025) Effectiveness and Safety of IVIG for the Treatment of HMGCR Immune‐Mediated Necrotizing Myopathy. Muscle & Nerve, 71, 392-397. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, R., Lin, W., Xie, Q. and Yin, G. (2025) Targeted Therapy for Idiopathic Inflammatory Myopathy. Journal of Cachexia, Sarcopenia and Muscle, 16, e70143. [Google Scholar] [CrossRef] 
[26] Vaezi, Z. and Amini, A. (2025) Immune-Mediated Necrotizing Myopathy: A Systematic Review of Antibody-Specific Mechanisms and Treatment Outcomes. Cureus, 17, e97933. [Google Scholar] [CrossRef] 
[27] Glennie, M.J., French, R.R., Cragg, M.S. and Taylor, R.P. (2007) Mechanisms of Killing by Anti-Cd20 Monoclonal Antibodies. Molecular Immunology, 44, 3823-3837. [Google Scholar] [CrossRef] [PubMed]
[28] Landon-Cardinal, O., Allenbach, Y., Soulages, A., Rigolet, A., Hervier, B., Champtiaux, N., et al. (2019) Rituximab in the Treatment of Refractory Anti-HMGCR Immune-Mediated Necrotizing Myopathy. The Journal of Rheumatology, 46, 623-627. [Google Scholar] [CrossRef] [PubMed]
[29] Anquetil, C., Boyer, O., Wesner, N., Benveniste, O. and Allenbach, Y. (2019) Myositis-Specific Autoantibodies, a Cornerstone in Immune-Mediated Necrotizing Myopathy. Autoimmunity Reviews, 18, 223-230. [Google Scholar] [CrossRef] [PubMed]
[30] Xiong, A., Yang, G., Song, Z., Xiong, C., Liu, D., Shuai, Y., et al. (2021) Rituximab in the Treatment of Immune-Mediated Necrotizing Myopathy: A Review of Case Reports and Case Series. Therapeutic Advances in Neurological Disorders, 14, 1-11. [Google Scholar] [CrossRef] [PubMed]
[31] McAtee, C.L., Lubega, J., Underbrink, K., Curry, K., Msaouel, P., Barrow, M., et al. (2021) Association of Rituximab Use with Adverse Events in Children, Adolescents, and Young Adults. JAMA Network Open, 4, e2036321. [Google Scholar] [CrossRef] [PubMed]
[32] Labrosse, R., Barmettler, S., Derfalvi, B., Blincoe, A., Cros, G., Lacombe-Barrios, J., et al. (2021) Rituximab-Induced Hypogammaglobulinemia and Infection Risk in Pediatric Patients. Journal of Allergy and Clinical Immunology, 148, 523-532.e8. [Google Scholar] [CrossRef] [PubMed]
[33] Varley, C.D. and Winthrop, K.L. (2021) Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections). Current Rheumatology Reports, 23, Article No. 74. [Google Scholar] [CrossRef] [PubMed]
[34] Zeng, R., Glaubitz, S. and Schmidt, J. (2022) Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options. Neurotherapeutics, 19, 911-921. [Google Scholar] [CrossRef] [PubMed]
[35] Bergua, C., Chiavelli, H., Allenbach, Y., Arouche-Delaperche, L., Arnoult, C., Bourdenet, G., et al. (2019) In Vivo Pathogenicity of IgG from Patients with Anti-SRP or Anti-HMGCR Autoantibodies in Immune-Mediated Necrotising Myopathy. Annals of the Rheumatic Diseases, 78, 131-139. [Google Scholar] [CrossRef] [PubMed]
[36] Mammen, A.L., Amato, A.A., Dimachkie, M.M., Chinoy, H., Hussain, Y., Lilleker, J.B., et al. (2023) Zilucoplan in Immune-Mediated Necrotising Myopathy: A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial. The Lancet Rheumatology, 5, e67-e76. [Google Scholar] [CrossRef] [PubMed]
[37] Khalesi, N., Korani, S., Korani, M., Johnston, T.P. and Sahebkar, A. (2021) Bortezomib: A Proteasome Inhibitor for the Treatment of Autoimmune Diseases. Inflammopharmacology, 29, 1291-1306. [Google Scholar] [CrossRef] [PubMed]
[38] Pasquale, R., Giannotta, J.A., Barcellini, W. and Fattizzo, B. (2021) Bortezomib in Autoimmune Hemolytic Anemia and Beyond. Therapeutic Advances in Hematology, 12, 1-19. [Google Scholar] [CrossRef] [PubMed]
[39] LeBlanc, Z.C., Clapp, A., Kaplan, S., Shawber, C.J. and Wu, J.K. (2025) Clinical Use and Toxicities of Bortezomib in Pediatric Patients: A Systematic Review. Frontiers in Pharmacology, 16, Article ID: 1661493. [Google Scholar] [CrossRef] [PubMed]
[40] Yang, M., Yuan, J., Wang, Y., Hao, H., Zhang, W., Wang, Z., et al. (2024) Treatment of Refractory Immune-Mediated Necrotizing Myopathy with Efgartigimod. Frontiers in Immunology, 15, Article ID: 1447182. [Google Scholar] [CrossRef] [PubMed]
[41] Alfaidi, N., Karmastaji, S., Matic, A. and Bril, V. (2024) FcRn Inhibitor Therapies in Neurologic Diseases. CNS Drugs, 38, 425-441. [Google Scholar] [CrossRef] [PubMed]
[42] Zhou, Q., Weng, R. and Xia, Y. (2022) Refractory Juvenile Dermatomyositis: Response to Tofacitinib. Medicina Clínica (English Edition), 158, 95-96. [Google Scholar] [CrossRef] 
[43] Zhou, Q.F., Luo, Y., He, T.Y., Ling, J.Y., Xu, Y.B., Yang, J. and Xia, Y. (2023) Analysis of the Clinical Characteristics and Therapeutic Effect of Refractory Juvenile Dermatomyositis to Tofacitinib. Chinese Journal of Pediatrics, 61, 538-542. (In Chinese)
[44] Charles‐Schoeman, C., Fleischmann, R., Davignon, J., Schwartz, H., Turner, S.M., Beysen, C., et al. (2015) Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients with Rheumatoid Arthritis versus Healthy Volunteers and Reversal by Tofacitinib. Arthritis & Rheumatology, 67, 616-625. [Google Scholar] [CrossRef] [PubMed]
[45] Wang, X., Wu, X., Tan, B., Zhu, L., Zhang, Y., Lin, L., et al. (2024) Allogeneic Cd19-Targeted CAR-T Therapy in Patients with Severe Myositis and Systemic Sclerosis. Cell, 187, 4890-4904.e9. [Google Scholar] [CrossRef] [PubMed]
[46] Volkov, J., Nunez, D., Mozaffar, T., Stadanlick, J., Werner, M., Vorndran, Z., et al. (2024) Case Study of CD19 CAR T Therapy in a Subject with Immune-Mediate Necrotizing Myopathy Treated in the RESET-Myositis Phase I/II Trial. Molecular Therapy, 32, 3821-3828. [Google Scholar] [CrossRef] [PubMed]
[47] Wang, X., He, X., Zhang, T., Liu, J. and Zhao, M. (2025) Latest Updates on Pathogenesis Mechanisms and Management Strategies for Cytokine Release Syndrome, Neurotoxicity, and Hemophagocytic Lymphohistiocytosis Related to CAR-T Cell Therapies. Annals of Hematology, 104, 3129-3151. [Google Scholar] [CrossRef] [PubMed]
[48] Dale, R.C., Brilot, F., Duffy, L.V., Twilt, M., Waldman, A.T., Narula, S., et al. (2014) Utility and Safety of Rituximab in Pediatric Autoimmune and Inflammatory CNS Disease. Neurology, 83, 142-150. [Google Scholar] [CrossRef] [PubMed]
[49] Ong, M.S., Rothman, D., Barmettler, S., Son, M.B., Lo, M., Roberts, J., et al. (2021) New-Onset Hypogammaglobulinaemia and Infectious Complications Associated with Rituximab Use in Childhood-Onset Rheumatic Diseases. Rheumatology, 61, 1610-1620. [Google Scholar] [CrossRef] [PubMed]
[50] Cheng, D.R., Barton, R., Greenway, A. and Crawford, N.W. (2016) Rituximab and Protection from Vaccine Preventable Diseases: Applying the Evidence to Pediatric Patients. Expert Review of Vaccines, 15, 1567-1574. [Google Scholar] [CrossRef] [PubMed]

为你推荐